Prostate Cancer - Cancer of the prostate, a common form of cancer, is a disease in which cancer (malignant) cells are found in the prostate. The prostate is one of the male sex glands and is located just below the bladder (the organ that collects and empties urine) and in front of the rectum (the lower part of the intestine).

EAU to launch online Prostate-Risk Indicator

Prostate Cancer :: EAU to launch online Prostate-Risk Indicator

The European Association of Urology (EAU) will soon launch an online prostate cancer risk assessment tool that will aid urologists, family physicians and men aged 55 years and older to properly evaluate the chance of developing prostate cancer.

Developed by the Rotterdam group of the European Randomized Study of Screening for Prostate Cancer (ERSPC), the Prostate-Risk Indicator is the first of its kind to predict the risks of men using a multivariate-based assessment.

Screening for prostate cancer, now the second leading cause of cancer death in men in Western Europe and the US, involves three diagnostic tests which may indicate prostatic biopsy, namely: the digital rectal examination (DRE), the transrectal ultrasonography (TRUS) and the serum PSA (Prostate Specific Antigen) level.

According to Prof. Fritz Schr?der, chairman of the ERSPC?s Scientific Committee, the indicator serves to provide men with balanced information on risks and benefits of undergoing testing for prostate cancer and whether he should proceed to consult his family doctor.

The indicator is based on data gathered in the Rotterdam area study on the first 6,288 participants who underwent screening. The men in the study were tested for PSA and any abnormalities in their prostates were also evaluated by DRE and ultrasound. The indicator works in four assessment levels and is applicable to men aged 55 to 74 years old, but not to men of African-American descent.

Levels 1 and 2 are meant to inform men who want an initial risk assessment. At Level 2, a PSA determination will have to be added and the question whether to consult a urologist could be answered at this stage. At Level 3, which takes into account the DRE result and TRUS determination of prostate volume, more solid information is provided about the chance of having a positive biopsy. Level 4 is applicable to men who have a positive biopsy and the assessment includes biopsy related parameters that will enable both urologist and patient to make a decision whether to undergo active treatment or active surveillance.

The English version of the Prostate-Risk Indicator, owned by the Dutch-run SWOP (Stichting Wetenschappelijk Onderzoek Prostaatkanker or the Foundation for Prostate Cancer Research), will be licensed to the EAU which in turn will offer the tool on one of its official website pages. A Dutch version of the indicator has been completed and both the Dutch and the English versions will be officially launched on September 15, which marks the European Prostate Awareness Day.

Recently posted related articles on Prostate Cancer :

1. Prostate Cancer :: Obesity and overweight linked to higher prostate cancer mortality
2. Prostate Cancer :: Men, don't skip your prostate cancer treatment appointments!
3. Prostate Cancer :: Radiation seed implant decreases risk of death over watchful waiting
4. Prostate Cancer :: Radiation after surgery keeps high-risk prostate cancer at bay
5. Prostate Cancer :: New research may show why some prostate cancer recurs after treatment
6. Prostate Cancer :: Prostate cancer increases hip fracture risk by eight times in 50 to 65 year-olds
7. Prostate Cancer :: IMRT better for sparing bladder when treating prostate cancer
8. Prostate Cancer :: Prostate cancer more likely to return in blacks than whites
9. Prostate Cancer :: Surgery may offer best chance of long-term prostate cancer survival
10. Prostate Cancer :: Using additional biopsy-scoring data may help determine prostate cancer prognosis